{
  "schemaVersion" : 2,
  "registerId" : "F2019L00634",
  "instrumentNumber" : "46/2019",
  "citation" : "Statement of Principles concerning rapidly progressive crescentic glomerulonephritis (Balance of Probabilities) (No. 46 of 2019)",
  "conditionName" : "rapidly progressive crescentic glomerulonephritis",
  "effectiveFrom" : "2019-05-27",
  "standardOfProof" : "Balance of Probabilities",
  "icdCodes" : [ ],
  "onsetFactors" : [ {
    "paragraph" : "9(1)",
    "text" : "having an infection from the specified list of infections within the two\r\nmonths before the clinical onset of rapidly progressive crescentic\r\nglomerulonephritis",
    "definedTerms" : [ {
      "term" : "specified list of infections",
      "definition" : "means:\r\n(a) bacterial infection;\r\n(b) hepatitis B;\r\n(c) hepatitis C;\r\n(d) human immunodeficiency virus infection; or\r\n(e) infective endocarditis."
    } ]
  }, {
    "paragraph" : "9(2)",
    "text" : "having an autoimmune disorder from the specified list of autoimmune\r\ndisorders at the time of the clinical onset of rapidly progressive\r\ncrescentic glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(3)",
    "text" : "having infiltration of the kidneys due to a disorder from the specified\r\nlist of infiltrative disorders at the time of the clinical onset of rapidly\r\nprogressive crescentic glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(4)",
    "text" : "having a renal disorder from the specified list of renal disorders at the\r\ntime of the clinical onset of rapidly progressive crescentic\r\nglomerulonephritis",
    "definedTerms" : [ {
      "term" : "specified list of renal disorders",
      "definition" : "means:\r\n(a) fibrillary glomerulonephritis;\r\n(b) immunoglobulin A nephropathy (including mesangial IgA\r\nglomerulonephritis);\r\n(c) immunoglobulin G4-related kidney disease (including tubulointerstitial\r\nnephritis and membranous glomerulonephritis secondary to\r\nimmunoglobulin G4-related disease);\r\n(d) membranoproliferative glomerulonephritis; or\r\n(e) membranous glomerulonephritis."
    } ]
  }, {
    "paragraph" : "9(5)",
    "text" : "having a malignant neoplasm at the time of the clinical onset of rapidly\r\nprogressive crescentic glomerulonephritis",
    "definedTerms" : [ ]
  }, {
    "paragraph" : "9(6)",
    "text" : "taking a drug from the specified list of drugs within the seven days\r\nbefore the clinical onset of rapidly progressive crescentic\r\nglomerulonephritis",
    "definedTerms" : [ {
      "term" : "specified list of drugs",
      "definition" : "means:\r\n(a) benzylthiouracil;\r\n(b) carbimazole;\r\n(c) cocaine adulterated with levamisole;\r\n(d) D-penicillamine;\r\n(e) hydralazine;\r\n(f) levamisole;\r\n(g) propylthiouracil; or\r\n(h) rifampicin."
    } ]
  } ],
  "aggravationFactors" : [ {
    "paragraph" : "9(7)",
    "text" : "inability to obtain appropriate clinical management for rapidly\r\nprogressive crescentic glomerulonephritis",
    "definedTerms" : [ ]
  } ]
}